Table 3.
CSF concentrations of cytokines correlating with INL HRF count.
| NIND | I-HRFlow | I-HRFhigh | NIND vs. I-HRFlow (p-value) a | NIND vs. I-HRFhigh (p-value) a | I-HRFlow vs. I-HRFhigh (p-value) a | |
|---|---|---|---|---|---|---|
| Disease duration at CSF (m) | n.a. | 4.9 ± 2.5 | 2.5 ± ± 3.1 | n.a. | n.a. | 0.4 |
| EDSS | n.a. | 1.5 (1.0-3.0) | 2.5 (1.5-2.5) | n.a. | n.a. | 0.1 |
| Brain MRI gad+ (%) | n.a. | 25.0% | 54.6% | n.a. | n.a. | 0.6 |
| Spinal cord MRI gad+ (%) | n.a. | 25.0% | 18.2% | n.a. | n.a. | 1.0 |
| Radiological activity (%) | n.a. | 37.5% | 45.5% | n.a. | n.a. | 1.0 |
| Clinical activity (%) | n.a. | 37.5% | 63.6% | n.a. | n.a. | 0.4 |
| Disease activity (%) | n.a. | 62.5% | 81.8% | n.a. | n.a. | 0.6 |
| CXCL-2 (pg/mL) | 4.1 ± 1.2 | 7.4 ± 4.2 | 3.6 ± 2.2 | 0.2569 | 0.8726 | 0.0251 |
| CXCL-13 (pg/mL) | 0.8 ± 0.4 | 4.5 ± 5.7 | 14.0 ± 13.6 | 0.0217 | <0.0001 | 0.4280 |
ONIND, other not inflammatory neurological diseases; I-HRFlow, RRMS patients with INL HRF count ≤17.5; I-HRFhigh, RRMS patients with INL HRF count >17.5.
ap-values from the Kruskal–Wallis test corrected with multiple-comparison Dunn’s test; n.a., not applicable.